| Trial ID: | L0361 |
| Source ID: | NCT00323414
|
| Associated Drug: |
Polyunsaturated Fatty Acids
|
| Title: |
Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
Has Results
|
| Results: |
https://ClinicalTrials.gov/show/NCT00323414/results
|
| Conditions: |
Fatty Liver
|
| Interventions: |
Drug: Polyunsaturated fatty acid (Opti-EPA)|Drug: Placebo
|
| Outcome Measures: |
Number of Participants With Improvement of >= 2 Points in NAFLD Activity Score (NAS)|Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) Values|Aspartate Amino Transferase (AST) Levels|Alanine Amino Transferase (ALT) Levels|Blood Glucose Levels|HbA1C Levels
|
| Sponsor/Collaborators: |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
All
|
| Age: |
18 Years and older ?? (Adult, Older Adult)
|
| Phases: |
Phase 2
|
| Enrollment: |
37
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
|
| Start Date: |
April 2006
|
| Completion Date: |
December 2011
|
| Results First Posted: |
February 23, 2018
|
| Last Update Posted: |
February 23, 2018
|
| Locations: |
MetroHealth Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT00323414
|
